产品说明书
Valganciclovir HCl
 |
同义名 : | Valganciclovir (hydrochloride);Ro 107-9070/194;Valganciclovir hydrochloride |
| CAS号 : | 175865-59-5 | |
| 货号 : | A247777 | |
| 分子式 : | C14H23ClN6O5 | |
| 纯度 : | 98% | |
| 分子量 : | 390.823 | |
| MDL号 : | MFCD08460118 | |
| 存储条件： |
粉末 Keep in dark place,Inert atmosphere,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 50 mg/mL(127.94 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 50 mg/mL(127.94 mM) |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Cytomegalovirus (CMV) is a herpes virus that causes disease in severely immunocompromized patients. The ganciclovir prodrug valganciclovir, avalyl ester of ganciclovir, is rapidly converted to ganciclovir during the first pass process in the gut wall and is used to treat CMV infection. In vitro, valganciclovir inhibited the uptake of glycylsarcosine in a dose-dependent manner with IC50 values of 1.69 ± 0.30 mM in Caco-2 cells and 0.046 ± 0.005 mM in SKPT cells, respectively. Likewise, it inhibited the uptake of the dipeptide in a dose-dependent manner with IC50 values of 2.84 ± 0.42 mM in PEPT1-expressing cells and 0.176 ± 0.012 mM in PEPT2-expressing cells[3]. For patients with CMV viremia, valganciclovir (900 mg b.i.d. for 7 days) was effective as pre-emptive therapy with rate of viral clearance at 28 days of 89.5%[4]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02227641 | Patients Undergoing Allogeneic... 展开 >> Stem Cell Transplantation 收起 << | Phase 1 Phase 2 | Unknown | March 2017 | Germany ... 展开 >> Medical Center Augsburg Recruiting Augsburg, Germany, 86156 Contact: Christoph Schmid, MD, PhD 0049 821 4002736 Principal Investigator: Christoph Schmid, MD, PhD Charité University Hospital Berlin Recruiting Berlin, Germany, 13353 Contact: Armin H Gerbitz, MD, PhD ++49 30 450565256 armin.gerbitz@charite.de Contact: Lutz Uharek, MD, PhD lutz.uharek@charite.de Sub-Investigator: Lutz Uharek, MD, PhD Principal Investigator: Armin Gerbitz, MD, PhD Universitiy Hospital Erlangen Recruiting Erlangen, Germany, 91054 Contact: Anita Kremer, MD, PhD ++49 9131 8543183 anita.kremer@uk-erlangen.de Contact: Bernd Spriewald, MD, PhD ++49 9131 8543116 bernd.spriewald@uk-erlangen.de Sub-Investigator: Katja San Niccolo, MD University of Mainz Recruiting Mainz, Germany, 55131 Contact: Eva Wagner, MD Principal Investigator: Eva Wagner, MD University of Munich LMU Recruiting Munich, Germany, 81377 Contact: Johanna Tischer, MD 0049 89 70954240 Principal Investigator: Johanna Tischer, MD University of Regensburg Not yet recruiting Regensburg, Germany, 93053 Contact: Ernst Holler, MD, PhD 0049 941 9445570 Principal Investigator: Ernst Holler, MD, PhD 收起 << |
| NCT00078559 | Kidney Transplantation ... 展开 >> Kidney Disease 收起 << | Phase 1 Phase 2 | Completed | - | United States, Wisconsin ... 展开 >> University of Wisconsin - Department of Medicine Madison, Wisconsin, United States, 53792-1735 收起 << |
| NCT02188719 | Liver Transplantation | Phase 1 | Recruiting | January 2022 | United States, California ... 展开 >> University of California, San Francisco Recruiting San Francisco, California, United States, 94143 Contact: Monique Koenigsberg 415-502-3016 Monique.Koenigsberg@ucsf.edu Principal Investigator: Sandy Feng, MD, PhD United States, Illinois Northwestern University Recruiting Chicago, Illinois, United States, 55905 Contact: Patrice Al-Saden 312-503-1058 palsaden@northwestern.edu Principal Investigator: Josh Levitsky, MD United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Julie Gecox Hanson, CCRP 507-293-6592 Gecox.Julie@mayo.edu Principal Investigator: Timucin Taner, MD, PhD 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.56mL 0.51mL 0.26mL |
12.79mL 2.56mL 1.28mL |
25.59mL 5.12mL 2.56mL |
| 参考文献 |
|---|